You need JavaScript to view this

The preparation of a radionuclide labeled peptide {sup 125}I-WH16 and its characters of binding to a human liver cancer cell line HepG2 in vitro

Journal Article:

Abstract

Objective: To investigate the binding characters of a radionuclide labeled peptide {sup 125}I-WH16 which is affinitive to hepatocarcinoma cells in order to explore the potential feasibility of this artificially synthesized peptide to be a targeting reagent in diagnosis and therapy of liver cancer. Methods: 1) WH16 was labeled with Na{sup 125}I using Iodogen method, then isolated and identified with HPLC; 2)a. The tests of cell number (or time of incubation)- to-binding counts between {sup 125}I-WH16 and HepG2 cells were carried out in order to obtain better conditions for next in vitro tests; b. The average binding counts of {sup 125}I-WH16 treated HepG2 cells and L02 cells were compared in order to inspect the binding specificity between {sup 125}I-WH16 and HepG2 cells; c. A test of saturation of binding between {sup 125}I-WH16 and HepG2 cells was carried out in order to investigate the binding affinity between {sup 125}I-WH16 and HepG2 cells. Results: 1) The labeling rate of {sup 125}I was 50%. The specific activity of {sup 125}I-WH16 was 8.21x10{sup 15} Bq/mol. The radiochemical purity was 95% and the remnant radiochemical purity after a storage for 24 h at -20 degree C was 95%. The radioactive concentration was 6.64 x 10{sup 9}  More>>
Authors:
Sha, Luo; Xiaohua, Zhu; Hua, Wu; [1]  Bing, Jia; Jing, Du; Fan, Wang
  1. Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong Univ. of Science and Technolgoy, Wuhan (China)
Publication Date:
Dec 15, 2004
Product Type:
Journal Article
Resource Relation:
Journal Name: Chinese Journal of Nuclear Medicine; Journal Volume: 24; Journal Issue: 6; Other Information: 1 fig., 2 refs
Subject:
38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEAR CHEMISTRY; AFFINITY; CHEMICAL ACTIVATION; CHEMICAL PREPARATION; CHEMICAL REACTION YIELD; HEPATOMAS; IODINE; IODINE 125; LABELLING; ORGANIC IODINE COMPOUNDS; PEPTIDES; PRODUCT LABELING; RADIOPHARMACEUTICALS; SPECIFICITY; TUMOR CELLS
OSTI ID:
20972643
Country of Origin:
China
Language:
Chinese
Other Identifying Numbers:
Journal ID: ISSN 0253-9780; CITCDE; TRN: CN0800206002079
Submitting Site:
INIS
Size:
page(s) 344-345
Announcement Date:
Feb 06, 2008

Journal Article:

Citation Formats

Sha, Luo, Xiaohua, Zhu, Hua, Wu, Bing, Jia, Jing, Du, and Fan, Wang. The preparation of a radionuclide labeled peptide {sup 125}I-WH16 and its characters of binding to a human liver cancer cell line HepG2 in vitro. China: N. p., 2004. Web.
Sha, Luo, Xiaohua, Zhu, Hua, Wu, Bing, Jia, Jing, Du, & Fan, Wang. The preparation of a radionuclide labeled peptide {sup 125}I-WH16 and its characters of binding to a human liver cancer cell line HepG2 in vitro. China.
Sha, Luo, Xiaohua, Zhu, Hua, Wu, Bing, Jia, Jing, Du, and Fan, Wang. 2004. "The preparation of a radionuclide labeled peptide {sup 125}I-WH16 and its characters of binding to a human liver cancer cell line HepG2 in vitro." China.
@misc{etde_20972643,
title = {The preparation of a radionuclide labeled peptide {sup 125}I-WH16 and its characters of binding to a human liver cancer cell line HepG2 in vitro}
author = {Sha, Luo, Xiaohua, Zhu, Hua, Wu, Bing, Jia, Jing, Du, and Fan, Wang}
abstractNote = {Objective: To investigate the binding characters of a radionuclide labeled peptide {sup 125}I-WH16 which is affinitive to hepatocarcinoma cells in order to explore the potential feasibility of this artificially synthesized peptide to be a targeting reagent in diagnosis and therapy of liver cancer. Methods: 1) WH16 was labeled with Na{sup 125}I using Iodogen method, then isolated and identified with HPLC; 2)a. The tests of cell number (or time of incubation)- to-binding counts between {sup 125}I-WH16 and HepG2 cells were carried out in order to obtain better conditions for next in vitro tests; b. The average binding counts of {sup 125}I-WH16 treated HepG2 cells and L02 cells were compared in order to inspect the binding specificity between {sup 125}I-WH16 and HepG2 cells; c. A test of saturation of binding between {sup 125}I-WH16 and HepG2 cells was carried out in order to investigate the binding affinity between {sup 125}I-WH16 and HepG2 cells. Results: 1) The labeling rate of {sup 125}I was 50%. The specific activity of {sup 125}I-WH16 was 8.21x10{sup 15} Bq/mol. The radiochemical purity was 95% and the remnant radiochemical purity after a storage for 24 h at -20 degree C was 95%. The radioactive concentration was 6.64 x 10{sup 9} Bq/ L; 2) a. The binding of {sup 125}I-WH16 to HepG2 cells was cell number dependent and the optimal time of incubation was 3 h; b. There were obvious differences between HepG2 cells and L02 cells in binding with {sup 125}I-WH16; c. The binding of {sup 125}I-WH16 to HepG2 cells showed saturability. Scatchard plotting suggested that HepG2 cells contained only one type of WH16 receptors. The concentrations of Kd and Bmax were (1.42 {+-} 0.28) nmol/L and (12.15 {+-} 0.63) pmol/L, respectively. Hill modulus from Hill plotting was 1.03, which was close to 1 and suggesting that one receptor may bind only one ligand molecule. Conclusions: The present study indicates that the preparation of {sup 125}I-WH16 is stable and has good specificity and high affinity of binding to HepG2 cell. It may be used as a targeting carrier in the diagnosis and therapy of liver cancer.(authors)}
journal = {Chinese Journal of Nuclear Medicine}
issue = {6}
volume = {24}
place = {China}
year = {2004}
month = {Dec}
}